share_log

Chardan Capital Upgrades Outlook Therapeutics to Buy, Announces $3 Price Target

Chardan Capital Upgrades Outlook Therapeutics to Buy, Announces $3 Price Target

Chardan Capital將Outlook Therapeutics上調至買入,宣佈3
Benzinga ·  02/15 20:29

Chardan Capital analyst Daniil Gataulin upgrades Outlook Therapeutics (NASDAQ:OTLK) from Neutral to Buy and announces $3 price target.

查爾丹資本分析師丹尼爾·加陶林將Outlook Therapeutics(納斯達克股票代碼:OTLK)從中性上調至買入,並宣佈了3美元的目標股價。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論